Alk-Abello AS (CHIX:ALKBc) Stock Price, Trades & News

Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	3.77
Equity-to-Asset	0.71
Debt-to-Equity	0.06
Debt-to-EBITDA	0.19
Interest Coverage	60.52
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	15	Distress Grey Safe
Beneish M-Score	-2.78	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	11.8
	3-Year EBITDA Growth Rate	41.1
	3-Year EPS without NRI Growth Rate	52.9
	3-Year FCF Growth Rate	184.6
	3-Year Book Growth Rate	17.3
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	15.54
	Future 3-5Y Total Revenue Growth Rate Estimate	13.52

Momentum Rank

9/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	0.67
	9-Day RSI	26.22
	14-Day RSI	60.67
	3-1 Month Momentum %	25.82
	6-1 Month Momentum %	13.37
	12-1 Month Momentum %	39.2

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.25
	Quick Ratio	2.01
	Cash Ratio	1.08
	Days Inventory	301.8
	Days Sales Outstanding	56.6
	Days Payable	24.99

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.62
	Dividend Payout Ratio	0.28
	Forward Dividend Yield %	0.62
	5-Year Yield-on-Cost %	0.62
	3-Year Average Share Buyback Ratio	-0.1
	Shareholder Yield %	1.14

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	67.76
	Operating Margin %	26.75
	Net Margin %	19.51
	EBITDA Margin %	32.13
	FCF Margin %	27.37
	OCF Margin %	33.36
	ROE %	20.84
	ROA %	14.79
	ROIC %	19.68
	3-Year ROIIC %	50.3
	ROC (Joel Greenblatt) %	45.82
	ROCE %	24.57
	Years of Profitability over Past 10-Year	7
	Moat Score	6

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	43.28
	Forward PE Ratio	33.69
	PE Ratio without NRI	43.28
	Shiller PE Ratio	169.29
	Price-to-Owner-Earnings	31.04
	PEG Ratio	1.13
	PS Ratio	8.45
	PB Ratio	8.47
	Price-to-Tangible-Book	11.63
	Price-to-Free-Cash-Flow	30.86
	Price-to-Operating-Cash-Flow	25.32
	EV-to-EBIT	30.83
	EV-to-EBITDA	25.85
	EV-to-Revenue	8.3
	EV-to-FCF	30.34
	Price-to-GF-Value	1.23
	Price-to-Projected-FCF	4.72
	Price-to-Median-PS-Value	1.46
	Price-to-Peter-Lynch-Fair-Value	1.73
	Price-to-Graham-Number	4.73
	Price-to-Net-Current-Asset-Value	28.6
	Earnings Yield (Greenblatt) %	3.24
	FCF Yield %	3.23
	Forward Rate of Return (Yacktman) %	20.89

GF Value™: kr208.28

CHIX:ALKBc

Warning Signs

Warning! GuruFocus detected 5 Medium warning signs with ALKBc. Try a 7-Day Free Trial to check it out.

Alk-Abello AS Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Alk-Abello AS Stock Events

Financials Calendars

Event	Date	Price (kr)
Third quarter earnings conference call for 2026	2026-11-18	In 143 days
Third quarter earnings results for 2026	2026-11-18	In 143 days
Second quarter earnings conference call for 2026	2026-08-20	In 53 days
Second quarter earnings results for 2026	2026-08-20	In 53 days
First quarter earnings conference call for 2026	2026-05-05 13:30	258.70 (+3.77%)
First quarter earnings results for 2026	2026-05-05	258.70 (+3.77%)
DKK 1.600000 Cash Dividend	2026-03-17	209.20 (+0.00%)
General meeting for 2026	2026-03-16 16:00	209.20 (+0.00%)
Annual report for 2025	2026-02-20 13:30	230.40 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-02-20 13:30	230.40 (+0.00%)

Show

Entries

Press Release

	Subject	Date
	U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy	2025-02-28
	ALK Announces U.S. FDA Approval of New AccuTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis	2024-10-07
	ALK to Become Sole Manufacturer and Distributor of Skin Antigen Test for Penicillin Allergy	2024-01-04
	U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents	2023-01-25
	The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma	2021-12-01
	ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients	2021-06-03
	U.S. FDA Approves ALK's RAGWITEK® (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis	2021-04-19
	Actress and Entrepreneur JoAnna Garcia Swisher and Husband, Former MLB World Champion Nick Swisher, Join New Campaign to Empower Allergy Sufferers to Take Control of Their Allergies	2020-10-28
	ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIOÂ® (ciprofloxacin otic suspension), the First and Only Single-Dose Treatment for Acute Otitis Externa (Swimmer's Ear)	2020-06-17
	ALK to Present New Phase 3 Data Demonstrating the Efficacy and Safety of RAGWITEKÂ® (short ragweed pollen allergen extract tablet for sublingual use 12 Amb a 1-U) Sublingual Allergy Immunotherapy (SLIT)-Tablets in Pediatric Patients at ACAAI 2019 Annual S	2019-11-08

10/Page

Articles on Alk-Abello AS

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.

Alk-Abello AS - Class B

Business Description